ConductScience.org, home

Paper41373641

From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.

Prados-Carmona A and 3 others. Int J Mol Sci, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies. Papers, record 41373641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41373641

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-09-25
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Prados-Carmona AAlvaro
2Husein-ElAhmed HHuseinhttps://orcid.org/0000-0001-7869-0206
3Navarro-Triviño FJFrancisco Joséhttps://orcid.org/0000-0002-5454-3671
4Ruiz-Villaverde RRicardohttps://orcid.org/0000-0002-0381-6174

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Dermatitis, AtopicMajor topic
Humans
Janus Kinase Inhibitors
Antibodies, Monoclonal
Signal Transduction
Cytokines

References182

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139080181Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.BioDrugs2024https://conductscience.org/library/papers/39080181PubMed
228670717Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.Allergy2018https://conductscience.org/library/papers/28670717PubMed
336630140Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).JAMA Dermatol2023https://conductscience.org/library/papers/36630140PubMed
436082590Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.Br J Dermatol2022https://conductscience.org/library/papers/36082590PubMed
525659898Modulation of pulmonary fibrosis by IL-13Rα2.Am J Physiol Lung Cell Mol Physiol2015https://conductscience.org/library/papers/25659898PubMed
639039360Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study.Dermatol Ther (Heidelb)2024https://conductscience.org/library/papers/39039360PubMed
740990093Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions.Allergy2026https://conductscience.org/library/papers/40990093PubMed
827956146Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2.J Mol Biol2017https://conductscience.org/library/papers/27956146PubMed
927490125The 'omics' revolution: redefining the understanding and treatment of allergic skin diseases.Curr Opin Allergy Clin Immunol2016https://conductscience.org/library/papers/27490125PubMed
1035948826Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis.Int J Dermatol2023https://conductscience.org/library/papers/35948826PubMed
1137908364Innate lymphoid cells: a new key player in atopic dermatitis.Front Immunol2023https://conductscience.org/library/papers/37908364PubMed
1240251175Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database.Sci Rep2025https://conductscience.org/library/papers/40251175PubMed
1338534078Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study.J Eur Acad Dermatol Venereol2024https://conductscience.org/library/papers/38534078PubMed
1438216802Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.Am J Clin Dermatol2024https://conductscience.org/library/papers/38216802PubMed
1532651105Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.J Dermatol Sci2020https://conductscience.org/library/papers/32651105PubMed
1639405928Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study.Int Immunopharmacol2024https://conductscience.org/library/papers/39405928PubMed
1726051792IL-33 and Thymic Stromal Lymphopoietin in mast cell functions.Eur J Pharmacol2016https://conductscience.org/library/papers/26051792PubMed
1837032446Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.Clin Exp Dermatol2023https://conductscience.org/library/papers/37032446PubMed
1938556434IL-4-induced decrease in both the number and CTLA-4 expression of Treg impairs suppression of Th2 type inflammation in severe atopic dermatitis.J Dermatol Sci2024https://conductscience.org/library/papers/38556434PubMed
2036559247OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.Pharmaceutics2022https://conductscience.org/library/papers/36559247PubMed

See all 182 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42909837Current Challenges in Atopic Dermatitis: An Italian Delphi Consensus with a Special Focus on Moderate Disease.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42909837PubMed
42511475Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.Int J Mol Sci2026https://conductscience.org/library/papers/42511475PubMed
41972685Gut Dysbiosis and the Molecular Landscape of the Gut-Skin Axis: Comparative Insights and Therapeutic Implications for Atopic Dermatitis and Psoriasis.Cells2026https://conductscience.org/library/papers/41972685PubMed
41897446From Dysbiosis to Inflammation: Gut Microbiota and Oxidative Stress in Atopic Dermatitis.Antioxidants (Basel)2026https://conductscience.org/library/papers/41897446PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41373641

GET https://conductscience.org/api/papers/v1/41373641/references?page=2